DEXCOM INC Earnings Per Share Disclosure
Years Ended December 31, | ||||||||
2017 | 2016 | 2015 | ||||||
Options outstanding to purchase common stock | 0.4 | 0.7 | 1.3 | |||||
Unvested restricted stock units | 2.7 | 3.7 | 4.1 | |||||
Senior convertible notes | 4.0 | — | — | |||||
Total | 7.1 | 4.4 | 5.4 | |||||
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2017 | Feb 27, 2018 | Showing above |
| 2016 | Feb 28, 2017 | |
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.